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A decline in the incidence and mortality of cervical cancer has been observed in most 
Western countries since the first third of the past century. This may be mainly attributed to 
the introduction of Pap test, that is considered one of the milestones in medicine. 
Nevertheless, worldwide burden of cervicocarcinoma is still enormous. This fact is well 
known among the scientific community, and has led to an extensive search for optional 
screening tools and predictive markers, currently under testing in different countries.  
 !	"
Modern research on Papillomavirus and Papillomaviruses began more than 150 years ago. 
In a famous paper, the Italian physician Rigoni(Stern analyzed death certificates of woman 
in Verona, during the period 1760(1839. He noted that cervical cancer was common among 
prostitutes, married women and widows but rare in virgins and nuns. He concluded that 
the development of this cancer should be related to sexual contacts. Later, in 1898, 
McFadyean and Hobday successfully transmitted canine oral papillomatosis, while Codeac 
transmitted warts from horse to horse, in 1901. In spite of a limited number of studies on 
Papillomavirus in subsequent decades, it was almost 80 more years later when this area of 
research engendered broad interest. In 1934 Rous and Beard noted that papillomas of 
domestic rabbits frequently converted to squamous(cell carcinomas. Although Rous 
conceptually preceded his contemporaries by several decades, the importance of his 
ponderous work was only acknowledged in 1966, when he received the Nobel Prize. Rous’s 
research was not specifically driven towards the agent causing rabbit papillomas, but using 
the frequent progression of rabbit papillomas to squamous(cell carcinomas, he provided an 
universal model to analyse cervical cancer development. From this point, a number of 
anecdotal reports of the malignant conversion of genital warts appeared in the medical 
literature and resulted in a persistent interest about the possible role of HPV infection in 
cervical cancer. This interest began more concrete with the failures in finding traces of 
Herpes simplex virus type 2 (HSV2) DNA in cervical cancer biopsies. These fails prompted 
the search for other potential infectious etiology. In the mild(1970s, within precancerous 
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cervical lesions, Meisels and Fortin firstly observed areas of koilocytic atypia, which they 
considered to be the cytopathic effect of HPV infection (Meisels & Fortin, 1976). 
In 1978, Della Torre et al., in Italy, and Laverty et al. in Australia, firstly demonstrated the 
presence of HPV virions within dense bodies of koilocytes, but deeper investigations were 
limited by the inability to propagate HPV in cultured cells or in simple animal models. By 
the end of 1970s, the revolutionary advent of recombinant DNA technologies and 
molecular cloning techniques, provided the key for advanced investigation on HPV 
biology, in order to confirm the role of Papillomavirus in cervical cancer etiology (Zur 
Hausen et al., 1977). Topically, in 1983, Harald zur Hausen et al., for the first time isolated 
HPV(16 from a cervical cancer biopsy and cloned its genome. Using HPV(16 sequence and 
Southern blotting technology, zur Hausen detected this genotype in about one(half of 
cervicocarcinoma biopsies (Boshart et al., 1984) and demonstrated the selective 
transcription of viral E6 and E7 oncoproteins in cervical cancer derived cell lines 
(Schwartz et al, 1985).  zur Hausen’s findings indirectly demonstrated the heterogeneity of 
the Human Papillomavirus family; this fact consequently led to the classification of 
genital HPVs into low(risk and high(risk oncogenic groups, in dependence of the ability 
to induce cancer. In 2008, Dr. zur Hausen will receive the Nobel prize for medicine. 
Actually, there is uniform agreement regarding the central role of high(risk HPV(infection 
in cervical cancer and the necessary but far from sufficient etiopathogenetic role of the 
virus in causing cervicocarcinomas (Solomon, 2003).  
The practical implication of this long series of studies is evident: an enormous  increase  in 
the quality of diagnostic approach of precursor lesions of cervical cancer and the 
development of preventive vaccine (Zur Hausen, 2002). 
#$%
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Papillomavirus are small, non(enveloped, epitheliotropic, double(stranded DNA viruses that 
can infect basal epithelial cells of the skin or inner lining of tissue and induce cellular 
proliferation in a specie(specific manner. More than 100 genotypes of Papillomavirus have 
been isolated and branded molecularly; they were categorized as cutaneous or mucosal type.  
Basing on their association with cervical cancer and precursor lesions, HPVs can be grouped 
in: “high risk” (HR) or “oncogenic” types (16, 18, 26, 31, 33, 35, 39, 45, 51, 53, 56, 58, 59, 66, 
68, 73, 82, and  “low(risk” (LR) or “non(oncogenic” types (6, 11, 40, 42, 44, 54, 61, 70, 72, 81, 
89), related to benign epithelial proliferation but not with cancer (Munõz et al., 2004, 2006). 
Among the nineteen oncogenic HPV types, five are most often found to be associated with 
cervical cancer; particularly, virus 16 is accountable for about half of cervicocarcinoma cases 
discovered in Northern America, Europe and Australia; viruses 18, 31, 33 and 45 are 
responsible for additional 30% of cases (Cliffort et al., 2003; De Sanjosè et al., 2007; Kraus et 
al., 2006).  All papillomaviruses show a common genetic structure: a single molecule of 
double(stranded circular DNA of about 7900 base(pairs genome, enclosed in a non(
evenloped icosahedral capsid. HPV(DNA encodes for eight open(reading frames (ORFs) 
which are transcribed from the single encoding DNA strand. The genome is functionally 
divided into three regions. The first is a non(coding one, referred as Long Control Region 
(LCR) or Upper Regolatory Region (URR). This section of HPV’s genome includes enhancer 
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and silencer sequences that regulate DNA replication by controlling the transcription of the 
ORFs. The second is the Early (E) Region, consisting of ORFs E1, E2, E4, E5, E6 and E7, 
which are implicated in viral replication and oncogenesis. The third is the Late (L) region, 
that encodes the L1 and L2 structural proteins. 
&
 
The global burden of HPV(associated disease is very high. At present, HPV infections 
represent the most common sexually transmitted disease (SMT) in the world (Snijders et al., 
2006). In the United States alone, it was estimated that 6.2 million of new infections occur 
annually, with an approximately prevalence of 20 million (Clifford et al., 2005). 
Within population, the prevalence of HPV infection in asymptomatic women is estimated to 
range from 2% to 44%; the highest peak was reported in women younger than 25 years of age. 
The vast majority of HPV infection is transient and resolves within 2 years without 
necessarily led to clinically significant cervical lesions. Only 10% of infected women remain 
HPV(positive within 5 years. In 2008 (the most recent year for which statistics are available), 
12,280 women in the United States had cervical cancer, and 4,021 died from the disease 
(Arbyn M et al., 2011). Rates of infection appears actually to be in incessant and rapidly 
increasing. 
Interest in HPV and cervical pathology is primarily justified by the morbidity and mortality 
caused by cervical epithelial cancer: cervicocarcinomas represents the second most common 
cancer among women worldwide. Its worldwide burden is enormous, with over 500,000 
new cases of cervical cancer diagnosed each year, and 280,000 deaths recorded (Jemal A et 
al., 2010; Parkin D et al., 2002). While in developed Western countries screening 
programmes have significantly reduced the incidence of disease, about 80% of 
cervicocarcinomas cases still occur in underdeveloped countries. 
The natural history of cervical cancer is characterized by a well(defined pre(malignant 
phases. These pre(malignant changes represent a spectrum of abnormalities ranging from 
Low(grade Squamous Intraepithelial Lesion (LSIL) to High(grade Squamous intraepithelial 
Lesions (HSIL). In the United States, about five hundred thousand high(grade precursors 
and 2(3 milion cases of low(grade lesions are referred for colposcopic assessment each year. 
The attendant costs for the management of these lesions was estimated in 3(6 billion dollars 
(Stoler, 2004). 
Prospective studies showed that infection with oncogenic HPVs precedes the development 
of cervical neoplasia, and that it’s necessary, even if not sufficient, to have HR(HPV infection 
to develop squamous intraepithelial lesion (SIL) or invasive cervical cancer (ICC). Virtually 
all cervical cancers test positive for HR(HPV DNA. Surprisingly, the etiopathogenetic role of 
HPV for cervical cancer is higher than smoke is for lung cancer and than Human Epatitis B 
(HBV) is for liver cancer (Carter JR et al., 2011). 
HR(HPVs increased the risk of developing cervical cancer in the order of 50(300 fold. A 
meta(analysis of Smith et al. shows that the overall prevalence of HR(HPVs in ICC is on the 
order of 87%, ranging from 86% to 94% by region. Overall, HR(HPVs prevalence in HSIL 
ranges from 78% in Asia to 88% in Europe (Smth et al., 2007). 
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There is a broad variation between the most prevalent HR(HPV types around the world. 
However, types 16 and 18 remain the most common in cervical lesions, causing 60(80% of all 
cervical cancers. HPV(16 ranges from 52% in Asia to 58% in Europe; HPV(18 ranges from 
13% in South(Central America to 22% in North America (Smith et al., 2007). 
It was originally believed that there was an irreversible progression of cervical disease from 
low(grade  to high(grade lesions and then invasive cervical cancer. However, through a 
much greater understanding of the natural history of HPV infection, we actually know that 
the majority of low(grade lesions would regress without treatment. To the necessary activity 
of HR(HPV, other co(factors such as smoking, long(term oral contraceptive pill use, human 
immunodeficiency virus (HIV) co(infection, high parity, Chlamydia Trachomatis and HSV 
infections, immune suppression as well as nutritional and dietary factors may be associated 
to induce cervical cancer. Generally, the vast majority of these condition adversely affects 
antigen(processing Langerhans cells, needed for cell(mediated immunity, or enhances HPV 






HPV life cycle is linked to the differentiation of the infected epithelial cell; it starts with the 
penetration of virions in the basal cells layers (stratum germinativum), through micro(
abrasions of the transformation zone of the cervix. The ability of HPVs to establish their 
genome in basal cells relies mainly upon E1, E2, E6 and E7 genes. Normally, when basal 
cells undergo cell division , it  loses contact with the basement  membrane and migrates into 
the suprabasal compartment, where it withdraws from the cell cycle and initiates a 
programme of terminal differentiation. In HPV infection, suprabasal cells fail to withdraw 
from the cell cycle. 
During acute infection, to replicate its genome and successfully produce infectious virions, 
HPV switches to amplify its DNA at high copy number, synthesises capsid protein and 
causes viral assembly, within the differentiated keratinocytes of the suprabasal layers of 
cervical epithelium. In this context many viral gene products are implicated. E7 has been 
shown to be necessary to induce suprabasal DNA synthesis, assisted by E5. E4 gene is 
essential for HPV(DNA replication and for the  expression of L1 and L2 genes. E4 also 
interrupts cytoplasmic cytokeratin network, causing condentation of tonofilaments at the 
cell periphery, and perinuclear cytoplasmic halo; the results is the koilocyte. Encapsidation 
of viral DNA, to generate viral progeny into differentiated cellular compartment,  is 
qualitatively dependent upon L2 gene. L2 may be also play a role during intracellular 
transport of virions, and  in the localization of viral DNA within host nucleus. 
During latent  infection, HPV stays as non(productive within the basal layer of the 
epithelium and establish itself as a low copy number episome, usually once molecule/cell 
cycle (Doorbar, 2005). At the basal and parabasal cellular levels only very little, if any, gene 
expression of the virus can be observed. Conversely, expression of early E1, E2, E4, E5, E6 
and E7 genes is evident within differentiated cells of the upper layers of the epithelium, 
which have lost the capacity to replicate their genome and are at no further risk of acquiring 
functional mutations. The above mentioned mechanism is a meticulous HPV strategy that 
allows maximal production of virions, causing almost no injury to infected host. The 
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situation changes radically if regulatory intracellular mechanisms driving the control of the 
viral are disturbed and deregulated. In this case, the expression of genes involved in the 
replication of viral genome occurs also in epithelial stem cells, which lost their capacity to 
differentiate. The inhibition of the differentiation process leads to a cellular state that cannot 
support the full viral life cycle. Interference of viral genes with cellular pathways that 
control replication and life cycle of epithelial cell might result in chromosomal instability. In 
epithelial stem cells with chromosomal instability, HPV DNA integrates into the host 
genome. HPV integration sites are randomly distributed over the whole genome, with a 
clear predilection for fragile sites (Wentzensen et al., 2004). Whether any property of the 
virus drives this integration event or whether it reflects random recombination events 
remain still unclear; however, two consequences of integration are certain: the loss of E2 
regulatory gene and the selective up(regulation of viral E6 and E7 oncogenes. Disruption or 
deletion of E2 gene, occurring during HPV(DNA integration, interferes with down(
regulation of E6/E7 transcription genes and leads to an increased and selective expression 
of E6/E7 oncoproteins, in replicating epithelial stem cells. As result, E6/E7 proteins bind to 
cell cycle regulators, stimulate cell(cycle progression and induce cellular instability 
(Doorbar, 2005). When E6 gene product binds to p53, physiological activities of p53, which 
governs G1 arrest and DNA repair or apoptosis, are abrogated (Doorbar, 2006; Tang et al., 
2006). E6 protein of non(oncogenic HPV types does not bind p53 at detectable levels and has 
no effect on p53 stability, . When E7 gene product binds to the hypophosphorilated 
form of the pRb, the result is the disruption of pRb(cellular transcription factor E2F(1 
complex, the release of E2F(1 and the transcription of genes whose products are required to 
enter in phase S of cellular cell cycle. Non(oncogenic E7 protein binds to pRb with a 
decreased affinity (Litchtig, 2006). Together E6/E7 proteins deregulate cell cycle checkpoints 
G1/S and G2/M. 
Host cells showing viral E6/E7 expression may acquire defects in differentiations, immortal 
phenotype, chromosomal instability and an increased probability of mutation allowing to 
invasion. Such described are obviously extraordinary molecular accidents occurring during 
HPV cell cycle and, in view of many HPV(infected cells, are extremely rare events. On the 
other hand, the continuous and deregulated E6/E7 activity in cervical stem cells 
compartments, enhances the selection and the growth of mutated cell clones. Then 
persistence represents the essential and indispensable requisite to develop cervical cancer. 
Numerous studies concerning HPV infection in immunocompromised population, reported 
that E6/E7 would also play an important role in the inhibition of the host cell immune 
response (Kraus et al., 2006), particularly by down(regulating the expression of Interleukin(8 
(IL(8). IL(8 is a T(cell chemoattractive molecule (Guess & Mc Cance, 2005), that also 
suppresses the expression of the Monocyte Chemoattractant Protein 1 (MCP(1) in epithelial 
cells of female genital tract (Biswas & Sodhi, 2002). E6/E7 would also favour the evasion of 
infected cells from the antiviral and antiproliferative activities of Tumor Necrosis Factor 




The concept of utilizing  exfoliative cytology to identify women with cervical cancer was 
introduced by Papanicolaou and Babes, in 1920s. Next, Papanicolaou refined the technique 
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and demonstrated that conventional cytology could also be used to identify precancerous 
lesions of the cervix. The shift from using cytology as a way to identify cases of invasive 
cervical cancer to using it to identify women with pre(neoplastic lesions was extremely 
significant. It meant that cervical cytology could be used to prevent cervical cancer, over 
than to identify cases in early phases. 
In the 1960s, cervical cytology began to be extensively used. In about 30 years, cytology(
based screening reduced the incidence of cervicocarcinomas by up to 75% in countries that 
have been able to realize quality(controlled screening programs (Arbyn et al., 2011). No 
improvements or modifications of the Pap test were instituted during this time, as there was 
no doubt that well(organized screening programs, realizing high compliance and good 
quality control, were effectual in saving lives. 
The process of change began when the article “Lax Laboratories” was published in the Wall 
Street Journal in 1987 (November, 2), by Bogdanich. The phrase “The Pap Test Misses Much 
Cervical Cancer Through Labs Errors”, implying that false negative Pap tests resulted largely 
from carelessness of doctors, alerted the public. The accuracy of cervical cytology began to be 
questioned. The article led to increased people awareness, and climaxed with the introduction, 
in 1988, of the governmental regulatory document known as CLIA 88 (Clinical Laboratory 
Improvement Act). CLIA 88 enforced regulations to ensure high quality testing 
At the same time, in 1988, the National Cancer Institute sponsored a workshop to address 
the standardization of diagnosis in cervical cytology. The workshop introduced a new 
classification system designated as “The Bethesda System” (TBS). TBS, further revised in 
1991 and 2001, provided a uniform format and offered a standardized terminology, 
specifically emphasizing communication of clinically relevant information (National Cancer 
Institute Group, 1989). TBS has been widely accepted and is endorsed by both Pathology 
and Gynecological Societies. 
In the 1990s, it was realized that the efficacy of Pap test have reached a nadir, and meta(
analyses indicated that both sensitivity and specificity of a single Pap test in detecting cervical 
intraepithelial neoplasia or invasive cancer is in the order of 80(85% and 76%, respectively 
(Stoler et al., 2001). A review of the UK program found that, within women developing 
invasive cervical cancer, 47% had an apparently adequate screening history during the 
previous 5 years (Sasieni et al., 1996); some of these patients also had a history of negative 
smear results. These considerations suggested that the frontiers of effectiveness of 
conventional cytology have been reached and that was imperative to improve the diagnostic 
assessment of the Pap test. This fact has been well recognized among the scientific community 
that emphasize the necessity to find other solutions to cope with this increasing problem. 
Prerequisites for an effective screening program is a high quality in sampling technique, in 
processing and in reporting. Basing on these considerations, technology entered in cytology 
practice with a variety of optional screening tolls to replace or complement conventional 










The low sensitivity of a single cervical smear is due to a variety of factors, including: 
incorrect or inadequate sampling of cervix; poor transfer of cells to the glass slide; non(
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representative sample placed on the slide; poor fixation. Particularly, sampling and 
preparing are together guilty for about two(third of false(negative tests (Cibas et al., 2008).  
To minimize false(negative cytology results and to improve the diagnostic accuracy of 
cervical cytology, some programs proposed to repeat the Pap test every year, to balance the 
relative limited sensitivity of conventional cytology; however, this conduct would 
compromise cost(efficacy of  Pap test and the possibility to use an algorithm with greater 
screening intervals and similar safety. New methods of collection and processing would 
need to surmount all these problems. 
Liquid(based cytology (LBC) was introduced in the mid(1990s, as a way to improve the 
performances of Pap test. By this technology, clinician does not prepare the specimen at the 
bedside by spreading the exfoliated cells onto a glass slide, but the cervical sampling device 
(i.e. spatula or brush) is rinsed in a vial containing a fixative(transport medium. In 
laboratory,  slides are prepared using an instrument that mixes the specimen and transfers 
an exact number of cells onto a filter membrane, with minimal cellular overlap. Then, the 
filter with the cells are transferred onto a slide and stained using the Pap stain (Abulafia et 
al., 2003). The automated process of such slides preparation prevents drying artefacts (very 
common in conventional Pap slides) and eliminates non(diagnostic debris, such as blood, 
mucus and inflammatory cells. Background material such as inflammatory exudates, 
cytolysis, microorganisms and tumor diathesis can still be identified but it does not obscure 
the epithelial cells  (Davey et al., 2006). 
To date, there are three currently FDA(approved LBC techniques, These include: SurePathTM 
System (TriPath Imaging Inc., Burlington, NC, USA), ThinPrep® System (Hologic, Crawley, 
UK) and MonoPrep System (MonoGen, Lincolnshire, IL) (Cibas et al., 2008). 
ThinPrep and SurePath methods are the most widely studied technologies in literature; their 
underlying principles are similar, the only difference being that ThinPrep collects samples 
into methanol(based preservative solution, while SurePath dispenses cells into ethanol(
based fluids. 
More than forty publications promote the use of these preparation methods. In particular, 
all the authors show statistically significant improvement (about 10% or more) of the 
diagnostic sensitivity of conventional cytology in all categories of cervical disease (Bernstein 
et al., 2001; Davey at al., 2007; Nance et al, 2007; Papillo et al., 2008.). 
Currently, LBC constitutes over 80% of cervical screening tests in USA. In 2003, the UK 
National Institute for Clinical Excellence (NICE) recommended the introduction of LBC as 
primary way to process samples in cervical cancer screening programs (Stoykova et al., 
2008). The National Health Service of the United Kingdom agreed to introduce LBC 
throughout the country, in view of the reduction of inadequate specimens from 9% with 
conventional cytology to 1(2% with LBC (Nance et al., 2007). 
LBC techniques improved the quality of the smear, being cytological evaluation and 
interpretation facilitated by the thin layer of evenly distributed cells. Abnormal cells are not 
hidden in thick areas of the slide; Then, will follow an increased detection of the lesions 
(such as HSIL lesions), a reduction of the number of false(negative diagnosis and the 
diminution of unsatisfactory specimens. Moreover, the availability of residual cellular 
material, preserved for several week at room temperature, is usefulness for additional 
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investigations, such as immunocytochemistry or molecular procedures. In the USA, the 
Consensus Guidelines for the Management of Women with Cytologic Abnormalities 
considered HPV(DNA testing on residual LBC specimen to be the preferred approach to 
managing women with ASC(US cytological results. This suggestion was based on the 
grounds that HPV(DNA reflex testing could offer the advantage that women do not need to 
return to additional clinical  examination (Wright at al., 2002).  
+	,"		"
Screening of Pap smears is monotonous. It was recognised that the monotony of screening 
large numbers of normal slides promotes periods of lack of attention during which 
abnormal cells may be disregarded. Among women who have cervical cancer and have been 
screened, 14% to 33% of the cases represent failure to detect abnormalities. It is therefore not 
surprising that great efforts have been made to automate also this aspect of cervical cancer 
screening. The aim of computer(assisted reading of cervical smears is to increase the 
sensitivity of cytological testing by finding cells known to be very difficult to detect in 
conventional slides. This technology should also increase productivity by excluding normal 
slides or part of the slides from manual screening and by selecting most atypical images to 
be checked by cytologists (Dunton, 2000). 
In the mid(1990s two automated devices, based on traditional computer image technology 
and neural network software, have been subjected to extensive multicentre trials and 
subsequently approved by the American Food and Drug Agency for screening cervical 
smears: PAPNET system (Neuromedical Sciences Inc, Amsterdam ) and AutoPap 300 
(NeoPath Inc, Redmond Washington USA). Both are interactive systems, which select 
smears for manual review by the screener. They were initially approved for quality control 
or supplementary screening of cervical smears. Subsequently they were admitted for 
primary screening. 
PAPNET was introduced as a pre(screening method of conventional Pap smears. The 
smears were analysed using a combination of algorithmic and neural network programs; 
then, 128 images of the most abnormal looking cells or cell groups were selected for 
inspection by the screener. 
The images were stored on compact disc and viewed by the screener on a video monitor 
placed in the laboratory. The screener triages the images and decides whether the slide is 
negative or requires manual review. Those slides which were triaged negative were not 
subjected to manual microscopic review. 
AutoPap was also designed to also pre(screen conventional slides. This technology uses a 
computer algorithm method to classify and score glass slides to overall level of abnormality. 
All slide were processed through the device and then, on the basis of “abnormality index”, 
they were ranked in descending order of potential abnormality and broken into quintiles. 
This system, now manufactured by TriPath inc. and called FocalPoint®, was designed to 
look for abnormalities slide by slide and to rule out the 25% of slides with the lowest risk. 
These slides were automatically excluded from the list of those requiring manual 
microscopic review thus reducing the screener’s workload by 25%. Slides with the most 
severe abnormalities were completely reviewed by scientists. 
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FocalPoint is intended to be used on both conventionally(prepared and SurePath™ cervical 
cytology slides. This system analyses the samples using a series of algorithms and assigns a 
score to the sample. The sample is then graded into a group called “No Further Review” 
(NFR) or into one of 5 risk categories. The purpose of this assignation is to make 
unnecessary to look at the NFR category. Cytoscreeners can instead concentrate themselves 
on looking at the slides graded as abnormal. The operator is guided to the areas containing 
the cells of interest (Fields of View/FOV) which have been detected by the system. 
Recently, Cytic Corporation developed its computer assisted system, the ThinPrep Imager®, 
which received FDA approval for use with ThinPrep slides. A bench(op image processor 
analyses ThinPrep slides, which were reviewed by  cytotechnologists, by using a microscope 
with a motorized stage. Special software drives the reviewer to the 22 most abnormal fields 
on the slides. Full manual review is required only if any of the 22 fields contain a suspicious 
or abnormal cell. 
Devices of computer(assisted screening were tested in extensive multicentre  trials 
comparing automated and manual screening of the same slides. All trials found that 
automated systems were at least as sensitive as manual screening; however, in automation 
more smears could be analysed per unit of time. On the other hand, due to high 
development costs, these systems were not found to be cost effective for the use in 
laboratories processing less than 50,000 smears per annum; this fact excluded many 




The awareness of the viral origin of cervicocarcinoma, the refinement of the techniques for 
cytological diagnosis and the introduction of liquid(based medium for collection of 
cytological specimens has open new and interesting options to improve cervical cancer 
screening programs. 
The consciousness that cervical cancer is a multistep process and that it occurs in women 
who have been infected with oncogenic HPVs, led to the development of molecular 
techniques able to identifying carcinogenic Papillomavirus in cervical sample (Bosch et al., 
2002). The era of diagnosis based on aetiology was beginning. 
Serological assays to detect antibodies against HPV capsid or against functional protein 
received attention as investigational tools, both in epidemiological and clinical studies 
(Jochmus(Kudielka et al, 1989; Galloway, 1992). However, serology detected humoral 
immune response to HPV antigens, which may reflect cumulative exposure to HPV 
infection acquired in mucosal sites other than genital; moreover, it was unreliable to 
determine whether an HPV infection was present or past (Dillner J, 1999), by using 
serological tests.  So, an accurate diagnosis of HPV infection could only be based on the 
detection of viral nucleic acid. 
Testing for Human Papillomavirus by different molecular tools has been proposed as an 
adjunct or as an independent screening tool, with several potential advantages. Testing for 
the etiological agent of cervical cancer offers the opportunity to detect women at increased 
risk of cervical cancer at the stage of latent and subclinical infection, preceding by several 
months to years the clinical stages detectable by the Pap test. 
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Wide range of methods to detect HPV(DNA in cytological specimens are available. They 
evolved considerably in the last 25 years. Initial methods were based on direct probe 
hybridation technology, such as dot blot and Southern blot. Besides being labor(intensive 
and time(consuming, these techniques showed low sensitivity and required large amounts 
of DNA in clinical samples. So they have largely been superseded by amplification 
technology. Amplification techniques can be further classified into two separate 
categories:(i) target amplification assays (i.e., PCR, in which a target nucleic acid is 
amplified) and (ii) signal amplification assays (in which the signal generated from each 
probe is increased by a compound(probe or branched(probe technology). To date, all the 
above methodologies (Figure 1) have been applied to HPV detection field (Zappacosta et al., 
2008).  
 
Fig. 1. Technology assessment in cervical cancer screening 
-	
 	
The first method for HPV detection was the Southern blot (Sb). Sb utilizes enzymes to break 
HPV(DNA chain extracted from the specimen. The product, integrated into a gel, is 
subjected to electrophoresis, that separates viral DNA basing on the size of each fragment. 
DNA fragments are next transferred to a nitrocellulose membrane and hybridized with HPV 
genomic probes, which are labelled with radioisotopes. In addition to poor labour 
applicability (reliance on radiolabelled probes) and high time(consuming, Sb procedures 
showed low sensitivity, mainly due to the need of large amounts of DNA in clinical 




$   hybridization (ISH) is a direct probe method that assess the presence of a target 
nucleic acid or gene expression within either paraffin(embedded tissue or cervical smear. 
The nucleic acid probes used in ISH are derivatized, typically with biotin, in multiple sites. 
Detection is frequently achieved employing a sandwich approach, involving streptavidin(
chromogen complexes. Improvements in sensitivity of ISH have been reached with 
fluorescent probe (FISH) utilization, in order to add a further amplification of the signal. The 
major advantages of ISH/FISH techniques is that HPV(DNA can be identified inside 
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specific cells (normal, koilocytes, neoplastic) and that viral physical status may also be 
determined (integration    episomal) (Hopman et al., 2005). Low sensitivity and 
specificity (30% and 72%, respectively), nucleic acid degradation during sample processing, 
and high time(consuming (due to multiple assays which must be carried out for HPV 
genotyping), are the main factors that make these techniques troublesome in its 
performances (Seedlacek, 1999). 
Laboratories using molecular assays for detection of infectious organisms should use 
standardized tools. In this context, the World Health Organization (WHO) has initiated an 
International Collaborative Study enrolling several laboratories worldwide (Pagliusi & 
Garland, 2007). The aim of developing HPV international standard reagents is to capacitate 
diagnostic laboratories to be able to validate their own assays and to determine their 
analytical sensitivity. Within surveillance studies, this standardization will allow 
comparison of HPV(DNA detection between different geographic localization, populations 
and anatomical sites over time. Standardization is particularly important in view of  post(
vaccine population responses data. 
High(throughput assays suitable for large(scale cervical cancer screening are currently based 
on two different amplification technologies: Polymerase Chain Reaction (PCR) and  
hybridization(based assays (i.g., Hybrid Capture 2 assay). The advantages and disadvantages 
of these basically different assays will be extensively discussed below together with the 




PCR is a selective target amplification assay capable of exponential and reproducible increase 
in the  HPV sequences present in biological specimens. The amplification process can 
theoretically produce one billion HPV(DNA copies from a single double(stranded molecule. 
after 30 cycles of amplification, For this reason, PCR has very high level of molecular 
sensitivity and permits the detection of less than 10 copies of HPV(DNA in a mixture 
There are two main approaches to detect HPV(DNA by PCR: type(specific PCR and 
consensus PCR. The latter are able to amplify sequences from several different HPV types, 
because they target conserved DNA regions in the HPV genome. The most extensively used 
PCR assay utilizes consensus primers that target a highly conserved region of HPV L1 
genome, thus amplifying a vast spectrum of HPV types in one reaction. Initially, most 
laboratories used PCR assay with degenerated primers pair MY09/11. These primers are 
now been replaced by a new set of oligonucleotides pool: GP5/6 and modified GP5+/GP6+, 
PGMY09/11 (modified MY09/11), SPF1/2, the last one especially appropriated for 
formalin(fixed paraffin(embedded tissue samples, which often offer a small amount of 
amplifiable DNA (Boulet et al., 2008; Perrons et al., 2005). Amplification with each of these 
primers provides different size amplification products, resulting in varying sensitivity for 
HPV(DNA detection. Although discrimination of sequence homology is better for longer 
sequences, and would theoretically permit improved HPV types resolution, shorter 
fragments tend to confer better sensitivity when potentially degraded specimens, such as 
paraffin(embedded tumor tissue, are used.  
Up to date literature reports clinical sensitivity of PCR protocols varying from 75% to 95% 
(Kulusingam et al., 2002), with a median of 82%. Of interest is the PCR versus HC2 data 
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obtained from ALTS study: on 278 cases of CIN3/cancer, PCR test employing the 
PGMY09/11 primers achieved clinical sensitivity and specificity of 87.4% and 55.6% 
respectively, while the corresponding value for HC2 test were 95.5 and 51.1% (Belinson et 
al., 2001; Zappacosta et al., 2010. 
The commercial assay by Roche Diagnostics, Amplicor® HPV test (Roche Molecular 
Systems, Inc., Branchburg, NJ, USA) has been recently released, although not yet FDA 
approved. The test is designed to amplify HPV DNA from 13 high(risk genotypes (16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), by using biotinylated  primers to define a sequence 
of approximately 165 bp in length within the polymorphic L1 region of the HPV genome, 
and to simultaneously assess the presence of human β(globin gene as a positive control. The 
test do not discriminate HPV genotypes specifically. In the International Papillomavirus 
Congress which took place in Mexico City during 2004, several studies showed data related 
to the utilization of Amplicor® test in two different LBC media (ThinPrep® and Surepath™) 
and illustrated the performance of the test in different clinical settings. Particularly, van den 
Brule at al., (Hessenlink et al., 2005) compared Amplicor® test with the GP5+/GP6+ PCR 
assay in cervical samples collected in PreservCyt® medium. The two tests gave similar 
results, but the sensitivity of Amplicor® appeared slightly higher. Roche assay and HC2 test 
gave identical results in detecting high(grade CIN (Monsonego J et al., 2005).  
The scenario changes when HPV genotyping is needed. HPV genotyping is now considered a 
relevant tool for women management, in order to identify persistent type(specific oncogenic 
HPV infection, and for the stratification of cancer risk. Among HPV(positive women, 20% to 
40% harbour at least two genotypes (Mendez et al., 2005). Interest in multiple HPV infections 
has recently increased as prophylactic vaccines against HPV have been introduced (Jenkins, 
2008). Moreover, the correct profiling of HPV types in patients with multiple infections is 
important to learn more about the natural history of cervical cancer. Constant progress in HPV 
typing based on PCR methods has been made over the past few years. The majority of 
available protocols uses degenerate and/or consensus primers, followed by the examination of 
the generated PCR product through sequence analysis, restriction fragments length 
polymorphisms analysis or hybridization with type(specific probes in different formats (such 
as the reverse line blot assay [van den Brule et al., 2002] or bead(based multiplex HPV 
genotyping method [Schmitt et al., 2006]). The use of these technologies offers the advantage of 
detecting a large spectrum of HPV types by a single PCR. However, they may be less efficient 
in detecting specific HPV types, in cases of multiple infections (Schmitt et al., 2010). 
Generally, amplification(based methods, mainly PCR, are currently the most sensitive 
methods for the detection of HPV(DNA. They are ideal instruments for research and 
epidemiological purposes, since they allow the detection of low viral load infections, also 
minimizing the risk of misclassification of HPV infection status. However, due to the 
frequent contamination problems and consequent false(positive results as well as to the 
costs which are still too high, they are not routinely applicable in diagnostic laboratories. In 
order to overcome these problems, Digene Diagnostics developed Hybrid Capture System 
DNA detection. 
&$" 
Hybrid Capture 2 (HC2, Qiagen, Valencia, CA)  is a simple, high(throughput, semi(automated 
HPV(DNA test, operating on the principle of signal amplification. HC2 is the only HPV test 
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currently approved by the US FDA. The method utilizes long (> 1 kb) single(strained RNA 
probes which are complementary to the entire HPV(DNA genomic sequence. DNA is firstly 
denatured  and subsequently mixed with RNA probe pool in a buffered solution. Two RNA 
probe pool are used. The test can be performed using both probe pool together or separately. 
Probe A recognizes non(oncogenic HPV types (6, 11, 42, 43, and 44); pool B identifies 
oncogenic HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). DNA(RNA complexes are 
immobilized onto microplates which has been coated with polyclonal IgG antibody that 
recognize specific DNA(RNA hybrids, at room temperature. The immobilized hybrids are 
then identified by a second DNA(RNA antibody, conjugated to alkaline phosphatise and 
bounded to a chemiluminescent substrate, CDP Star (Figure 2). Microplates are then 
transferred into a software program where results are analysed; in particular, CDP Star ligh is 
measured by a luminometer. The intensity of the light emitted by each specimen is expressed 
on a scale as RLUs (Relative Light Units), relative to the average reactivity measured in 
triplicate wells with a positive control containing 1.0 pg of HPV(16 DNA/ml.  
 
Fig. 2. Hybrid Capture 2 Technology. A ( HPV(DNA denaturation; B – single(stranded RNA 
probes recognizes oncogenic HPV(DNA; C ( DNA(RNA complexes are immobilized onto 
microplates coated with polyclonal IgG antibody; D – identification of immobilized hybrids 
by a second DNA(RNA alkaline phosphatise conjugated antibody, bounded to CDP star; E – 
a luminometer measures light emitted by the specimen (Digene(Qiagen website, modified)  
The first generation of HC assay (HC1) was a tube(based detection system and probed for 
only nine HR(HPV types. The analytical sensitivity of the assay was 50,000 copies of HPV(16 
DNA. 
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Several studies evaluated the clinical sensitivity and specificity of this first generation assay 
mainly against PCR and histology (Cavuslu et al., 1996; Cope et al., 1997; Shah et al., 1997). 
As expected, HC1 was less sensitive than PCR and other application techniques, but its 
specificity and positive predictive value (PPV) were higher than those of PCR. To improve 
the sensitivity of HC1, the Digene Corporation modified the first generation assay. The 
improved second(generation assay (Hybrid capture 2) is commercially available from the 
beginning of 1998. In this technology, the analytical sensitivity was increased to 1,000 HPV(
DNA copies. Studies comparing first and second generation of Hybrid Capture technology 
shoved concordance in 96.8%. Interestingly, in all discordant samples containing HPV(DNA 
types covered by the probes included in both assay generation, the RLU/cutoff value ratios 
obtained in the second(generation assay were very low, which would indicate that low HPV 
viral load was the reason that produced false(negative results in the first(generation assay. 
HC2 assay is actually considered more sensitive than HC1, as well as more rapid, easier to 
perform and thus more appropriate for the routinary detection of HPV infection. In 
addition, as RLU signal is proportional to the amount of HPV(DNA present in the specimen, 
HC2 assay could be occasionally used to deduce viral load, on a semi(quantitative basis. The 
main advantage of HC2 test is the high sensitivity and the abundant clinical data which 
allowed to its FDA approval. Moreover, since HC2 test is less affected by cross(specimen 
contamination than PCR, it don’t need for special laboratory (Carozzi et al., 2005; Cubie et 
al., 2005). On the other hand, there are many limitation to this techniques which have to be 
taken into account. First, the test cannot determine the specific HPV type present in the 
sample; this fact limits the recognition of persistent infection by the same viral type, which is 
the most important risk factor that induce cervical lesion to progress to invasive cancer. 
Second, at the standard FDA(approved cut(off of 1 pg/ml (RLU ≥1.0) and even at higher 
discriminating levels, RNA probes suffers from a cross(reactivity with non(oncogenic viral 
types and with certain oncogenic untargeted HPV types (53, 66, 67, 73) (Howard et al., 2004). 
Cross(reactivity with other oncogenic(HPV types might be beneficial for test sensitivity. On 
the other hand, cross(reactivity with non(cancer(causing types would have an adverse 
impact on clinical specificity and positive predictive value of the test, especially in 
population with a high prevalence of non(oncogenic types (Castle et al., 2003).  
During 2003, a prototype version of Hybrid Capture 3® (HC3), possibly the next generation 
of HC2, has been evaluated for the detection of CIN3 and cancer. HC3 was designed to 
minimize cross(reactivity with untargeted HPV types. HC3 showed slightly higher 
sensitivity that HC2 for the detection of CIN2+ lesions but equal specificity. Actually, HC3 
has not been marketed yet. 
HC2 technology is amenable to automation,  in case of high(volume screening use. The next(
generation Hybrid Capture® (NextGen, QIAensemble™, Qiagen Inc., Gaithesburg, MD), 
consists of a fully automated platform (JE2000™) which utilizes a reengineered HC2 test.  
The implementation of analytical specificity, the maintenance of  comparable levels of 
analytical sensitivity, the longer on(instrument stability of reagents, the detection of HPV(16 
and 18 at lower copy number, the reduction of assay time (< 2.5 hrs compared to up to 5 hrs 
for HC2), as well as the reduction of the cross(reactivity with non(oncogenic HPV types 
(Eder et al., 2009), are the main advantages of NextGen. To validate the use of NextGen 
within screening context, pre(clinical studies using specimens from patients with 
histologically confirmed CIN2+ lesions are needed.  
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Detection of oncogenic(HPV DNA is considered to be potentially useful in three clinical 
application: in population screening, as a primary test or in combination with cytology to 
detect cervical cancer precursors; in triaging, to select which cytological lesions must to be 
referred for colposcopy; in follow(up of women treated for high(grade intraepithelial lesion, 
to accurately identify patients with residual or recurrent lesion. 
In adjunct to cytology, the purpose of HPV(DNA assay is the detection of latent or 
subclinical infection among symptoms(free women. In 2001, Belinson et al., performed a 
large cross(sectional study (1997 women ageing 35(45) in order to compare the sensitivity of 
LBC and HC2 test for the detection of CIN2+ lesions (Belinson et al., 2001). Essentially, the 
rationale of the use of adjunctive HPV(DNA testing is based on the accepted concept of 
necessary causality of HPV in determining cervical cancer and on the basis of the very high 
negative predictive value (90(100%) of the combination HPV(DNA test/LBC. Combining 
HPV(DNA test with LBC improves the performance of Pap test alone, especially when 
cervical cytology is ambiguous (, ASC(US and LSIL lesions). Using mathematical models 
to evaluate clinical and economics outcomes. Goldie at al., concluded that using HPV(DNA 
test plus cytology in women ≥ 30 years of age were more effective in reducing cancer 
incidence. Combining molecular biology and LBC could also result in increasing the 
screening interval for women testing negative at both cytology and DNA testing. Longer 
screening intervals with more sensitive tests would be the strategy providing the most 
advantageous balance between benefits and costs (Goldie et al., 2004). 
In triage, the goal is to guide the management of patients with borderline or mildly 
diskaryotic smears (ASC(US and LSIL, respectively). ASC(US/LSIL Triage Study, a 
multicenter and randomized clinical trial sponsored by National Cancer Institute (NCI), 
evaluated three management strategies for women with ASC(US and LSIL cytological 
results: (i) immediate colposcopy; (ii) repeated cytology with referral to colposcopy if 
cytological findings showed HSIL lesion; (iii) HPV triage, with referral to colposcopy in case 
of HPV(DNA positivity (Rodriguez et al., 2008; Solomon et al., 2001). 
ALTS established that: (a) HPV(DNA triage is as sensitive as immediate colposcopy in 
HSIL+ detection; however, molecular testing would spare all HPV(negative women from 
emotional and financial weight of colposcopy. (b) repeating cytology, would refer more than 
two(third of ASC(US/LSIL abnormalities to colposcopy. ALTS study attested that HPV(
DNA method represents the best triage (Munoz et al., 2003). In the USA, HPV(DNA testing 
has been definitively integrated into cervical cancer screening programs and has become the 
standard of care in the triage of women over the age of 30, having minor cytological 
abnormalities (Wright et al., 2002); the rationale is the high proportion of HPV(DNA 
negative women (about 50%) among ASC(US group and the consequent extremely low risk 
of developing high(grade lesions. In this context, the role of DNA testing is to focus on those 
women ASC(US/DNA(positive in which colposcopic assessment is justified. 
Following treatment with cryosurgery, laser ablation or LEEP for HSIL cervical lesion, 5(
25% of patients may develop residual or recurrent high(grade disease (Kocken et al., 2011). 
Standard of care has been close cytological and colposcopic follow(up at 6, 12 and 24 months 
after treatment. However, since follow(up Pap test has a low specificity in detecting residual 
HSIL and given that HPV is cleared from the cervix following adequate treatment, DNA 
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testing has been evaluated to predict the presence of residual dysplasia (Nam et al., 2009). In 
a recent meta(analysis, Zielinski et al. considered 11 studies evaluating HR(HPV DNA 
testing in monitoring women after treatment of CIN2+ lesions. It has been shown that the 
association HPV(DNA testing/cytology reached a NPV of 99% (Zielinski et al., 2004). The 
adoption of such algorithm of surveillance would mean to focus colposcopy only on women 
positive for both Pap and DNA test. 
The consciousness of the necessary causality of HPV in determining cervical cancer defined 
new possible approaches to screen and prevent cervical cancer. In population screening, as a 
primary test, the purpose of HPV(DNA assay is the detection of latent or subclinical 
infection among symptom(free women (Rebolj et al., 2011). 
Most authors evaluated the performances of cytology (conventional or LBC) and HPV 
testing (PCR or HC2) in detecting CIN2+ lesions or cervical cancer in several populations. 
Despite various study design, various ranges of age, various HPV detection techniques, 
various cervical lesions prevalence rates, the global survey of results leads to three main 
conclusions: for CIN2+ or greater (CIN2+), HPV testing is more sensitive (88(98%    51(
86%) and has an higher negative predictive value (NPV) than cytology; specificity of DNA 
testing is lower than that of cytology (83(94%    92(99%); The sensitive and NPV of 
combined testing is near to 100%. The objective is then to start the primary screening by the 
most sensitive and automated test, HPV testing, and in second time to use the best 
specificity of cytology for diagnosis and triage (Arbyn et al., 2009). Women with abnormal 
smears would be immediately refer to colposcopy. Since a single negative HPV(DNA test 
reliably predicts a low risk of subsequent CIN2+, it would be justified to extend screening 
intervals.  (Bulkmans et al., 2007). 
Current European Guidelines for quality assurance in cervical cancer screening recommend 
implementation of pilot program with a validated HPV(DNA test within national organized 
cervical cancer screening programs and, if effective, permanent implementation of such 
programs (Arbyn et al., 2008). Longitudinal studies assessing the incidence of CIN2+ lesions 
are then essential to define the role of HPV testing in cervical cancer screening policies 
(Leinonen et al., 2009). Actually only baseline results of large randomized controlled trials 
are available. 
Anttila et al., evaluated the impact of primary HPV(DNA screening plus conventional 
cytology triage of HPV(DNA positive women and compared this cohort with cytology(
based screening cohoort. The study incorporated the population enrolled in organised 
screening programme for cervical cancer in Finland (Anttila et al., 2010). The evaluation was 
based on the total number of CIN3+ cases detected within five years after the invitation. The 
study, adding longitudinal information based on cancer registry files, showed that a single 
round of HPV primary test has been able to reduce the number of cases of invasive cervical 
cancer. These data suggest that using HPV DNA testing in primary screening, followed by 
cytology to triage HPV(DNA positive women, would represent an approach more sensitive 
than that based on cytology alone, in identifying CIN2+ lesions. 
In Sweden Naucler et al., explored the efficacy of 11 different screening strategies based on 
HPV DNA testing alone, cytology alone, and HPV DNA testing combined with cytology 
(Naucler et al., 2009). They showed that using HPV DNA testing as primary screening 
followed by cytological triage and repeating HPV DNA testing on DNA(positive/ cytology 
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negative women after at least 1 year would be a feasible strategy in primary cervical 
screening. 
The Italian NTCC (New Technology for Cervical Cancer) randomized controlled trial 
compared Human Papillomavirus testing (HC2) alone with conventional cytology as the 
primary cervical cancer screening test, in a total of about 49,200 having a median age of 42 
years (Ronco et al., 2008). Among women aged 35(60 years, HPV testing did not show a 
statistically significant extent   conventional cytology for the detection of CIN2+ lesion. 
Vice versa, increasing the cut(off for HPV(DNA positive results from 1 to 2 pg/ml, 
molecular testing arm showed a statistically significant increase in sensitivity, associated to 
a non statistically significant reduction of PPV. The sensitivity of HPV testing compared 
with conventional cytology was much larger among women aging 25(34 than among older 
women. Ronco et al., recommended the use of HPV testing as primary screening in women 
older than 35 years of age and a  preferable 2 pg/ml cut(off for HC2. In women aged less 
than 35 years, to avoid colposcopic overtreatment in HPV(positive/cytology negative 
patients, NTCC suggested 1 year molecular retesting (Figure 3). 
 
Fig. 3. Three different approaches to cervical cancer screening (Dillner J et al., BMJ 2008, 
modified) 
The consultation of the Medline database by formulating the queries “HPV testing”, 
“cervical cancer screening”, “cervical cancer”, “HPV testing in primary screening”, “HPV(
DNA screening test” allows to the following consideration: 
1. all the trials (except for NTCC) found that sensitivity of HPV(DNA testing was higher 
than that of cytology, in detecting CIN2+ lesion; 
2. all the trials state that NPP is higher for HPV testing than that for cytology. On the other 
hand, DNA testing is less specific than Pap test (89%   95%);  
3. HPV testing alone might induce an overtreatment, especially in the youngest 
population. The specificity for both HPV testing and cytology are clearly lower below 
30 years of age; 
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4. several studies showed that HPV(negativity alone or in combination with negative 
cytology triage would signify a longer disease interval against CIN2+ lesions than that 
being for cytology alone. In this context, it seems that a screening interval of five years, 
would be best choice. After five years, women testing DNA(negative would have a 
considerable lower risk for CIN2+ (0.25%) than woman having a normal Pap test 
(0.83%); 
5. cytology triage of HPV(DNA positive women, would be the best strategy for referring 
to colposcopy patients who were DNA(positive/cytology positive; 
6. it’s meaningless to perform cytology on DNA(negative women; in this case, double 
testing adds negligible protection compared to HPV testing alone; 
7. the better protection but the lower specificity of DNA testing implies that it should only 
be used in well(organized screening programs, in which the test is not used too 
frequently, or at too younger age (Dillner et al., 2008; Naucler et al., 2007; Naucler et al., 
2009).  
It’s our opinion that further evaluation of the risk of CIN2+ lesions with different 
combination of test and in relation to women’s age, would be the next step; then, it’s 
important to choose the best primary screening tool, taking in account costs and logistics of 
the single countries. 
The next step in research could be to improve the specificity of HPV(DNA testing by 





From the meta(analyses summarised above, it is clear that HPV(DNA testing is substantially 
more sensitive than cytology at detecting CIN2+ lesions. However, molecular testing is 
rather less specific than cytology. The main problem with DNA testing is the high 
prevalence of HPV(DNA positivity among female population, compared with the low 
number of women with transient infection which spontaneously would regress. These 
considerations suggest that the more sensitive test should be applied firstly (i.e. DNA 
testing), while the more specific test should be used only in HPV(positive women, in order 
to establish the correct management strategy. 
The approach of using HPV(DNA test as the sole primary screening modality has several 
advantages: HPV(DNA detection assays is an objective and automatable test with a 
dichotomous result; his allows for better quality of screening. Cytology can thus to be 
reserved for the 5(15% of women who are DNA(positive. This protocol would obtain cost 
savings through reductions in staff numbers, would reduce turnaround time of diagnosis, 
would avoid overtreatment and could permit a longer screening interval. For DNA testing, 
the requirement for adequate specimen sampling is less rigorous, when compared to 
cytology. Several studies evaluated the diagnostic accuracy of self(collected cervico(vaginal 
specimens (Ogilvie et al., 2005). With an overall sensitivity of 74% and specificity of 84%, 
self(taken sampling appears to be favourable in settings where sensitivity of cytology is 
typically less than 70%. Göh M et al., found that women prefer self(sampling to a clinician 
taken(sampling (Gök et al., 2010). These results suggest that self(sampling for HPV(DNA 
testing could be a valuable screening method to recruit women who refuse to attend 
clinician(based screening, and to improve population coverage of screening.  
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In developing countries, it seems unrealistic to introduce cytological screening and 
histopathological follow(up because of financial, technical and human limitations. 
Alternative methods of screening that would surmount barriers consisting in the “three(visit 
cytology(based approach” are needed which accurately predict the presence of cervical 
cancer or precursors (Table). Three requisites are essential in effective screening program: 
screening diagnosis and treatment should be provided on(site or in clinics accessible to the 
vast majority of women at risk of developing cancer; reproducible, validated, low(cost 
screening test should be available; screening should ensure high participation of women at 
risk for cervical cancer, by using appropriate educational programmes direct towards both 
health workers and population. While the first two conditions are essential in low(resource 
settings, the third is an universal requirement.  
In low(resource settings, a wide number of tests have been investigated over the years, as 
alternative screening tests to cytology. The four most widely studied alternative approaches 
are VIA (visual inspection with acetic acid), VILI (visual inspection with Lugol’s iodine), 












Requires adequate laboratory(based healthcare 
infrastructure, stringent training and quality 
control 
HPV testing 66%(100% 61%(96% 
High throughput, objective, reproducible and 
robust but currently expensive 
VIA 62%(80% 77%(84% Low cost, strict linkage to immediate treatment 
VILI 92% 85% Low cost, strict linkage to immediate treatment 
Colposcopy 44%(77% 85%(90% Expensive, inappropriate for low(resource settings 
Table. Ranges of sensitivity and specificity and characteristics of some screening methods. 




This technique involves the examination of the cervix with the naked eye and a bright light 
source, one minute after the application of 3(5% diluted acetic acid. Detection of well(
defined aceto(white areas close to the squamocolonnar junction, indicates a positive test. 
CIN and microinvasive cancer switch(on white following acetic acid application. Aceto(
whitening is essentially due to a reversible coagulation of intracellular proteins. The high 
concentration of intracellular proteins in neoplasia led to the dense aceto(whitening 
appearance. The main advantage of VIA is that it yields an immediate result, thus making it 
possible for treatment of abnormalities at the same visit (“screen(and(treat”approach). This 
method is also inexpensive and can be carried out by using modest  equipments, without 
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the need for laboratory infrastructures. Moreover, health workers can be rapidly trained to 
perform VIA (about ten days of courses duration). Several cross(sectional studies evaluated 
the accuracy of VIA in developing countries. Pooled estimates of the sensitivity of the test in 
detecting CIN2+ lesions vary from 62 to 80%, and the specificity from 77 to 84% (Arbyn et 
al., 2008; Gaffikin et al., 2008; Hovland et al., 2010). The greatest reduction in incidence and 





VILI involves the examination of the cervix the naked eye, in order to identify yellow areas 
after the application of Lugol’s iodine. A multi(centre study conducted in Africa and India 
showed a pooled sensitivity and specificity to detect CIN2+ lesions of 92% and 85% 
respectively, thus indicating a higher sensitivity than VIA but a similar specificity (Sarian et 
al., 2005).  
#-!,

Self(sampling method using self(collected vaginal samples is another alternative approach 
for primary screening in developing countries. The aim would be to try to increase the 
coverage of population when women do not undergo a gynaecological examination and 
when cytology screening is not available. Prevalence of oncogenic HPV types on self(
sampled vaginal material is about 5(10%, lower than for cervical smear; sensitivity for 
detecting CIN is also decreased in respect to cytology (Bekkers et al., 2006). However, for 
women not participating in programs of screening, vaginal self(sampling could be a good 
alternative and could reduce the risk of cervical cancer. 
&$%,.1

Screening must be linked to treatment to ensure its efficacy. This can be done using the 
traditional approach (screen, diagnosis, confirm and treat), intermediate approach (screen, 
diagnose and treat, with post(treatment biopsy confirmation) or screen(and(treat approach 
(treatment is based on the result of screening alone). A number of studies have investigated 
the screen(and(treat approach, and its safety and feasibility has been always confirmed. Basing 
on these studies, primary screening with HPV testing was considered an attractive approach.  
The use of HPV(DNA testing may prove more practical, especially when incorporated into 
strategies less dependent on existing laboratory infrastructure, such as low(resource setting 
and developing countries.  This “single(visit HPV(DNA testing strategy” requires screening 
sites to run the test on the day in which the sample is received and to allow for treatment of 
cervical lesion during the same visit (Levin et al., 2010). “See and treat’ approach would 
reduce the number of non(compliance to treatment and improve the efficiency of the 
program.  
No HPV(DNA existing test was deemed appropriate for the use in low(resources settings. 
For this reason, PATH (Seattle, WA, USA) and Qiagen entered into collaborative agreement 
and developed a new rapid, simple and affordable HPV(DNA test, specifically designed for 
developing countries. CareHPVTM is a signal(amplification assay that detects 14 different 
carcinogenic HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) in 2(5(hrs 
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processing time. The assay needs only a footprint, no mains electricity or running water. The 
short time(consuming would permit a same(day diagnostic evaluation, with treatment in a 
second visit, or even screening and treatment in the same day. CareHPV  can be performed 
by inexperienced, newly trained and minimally educated technicians, under suboptimal 
condition of temperature, humidity, lightning and space.  CareHPV use would be associated 
to fewer visits and transportation costs, and would reduce loss to follow(up. The rapid 
HPV(DNA, with its lower cost per test and greater sensitivity than conventional cytology 
now dominates other screening methods in developing countries. Levin CE et al., showed 
that accuracy for the detection of CIN2+ lesions was higher for careHPV test than for VIA. 
No differences has been detected between CareHPV and HC2, when screening women 30 
years of age and older (Levin et al., 2010). 
With the availability of vaccine against HPV(16 and 18, there has been enthusiasm for 
vaccination of young adolescent girls, also in disadvantage settings. Although preadolescent 
vaccination offers great hope for future generation, there exist a number of uncertainties that 
will persist for the next decades, including the need for drastically lower vaccine prices and 
creative financing sources to support vaccination costs. For the older women, the best option 
to reduce deaths from cervical cancer will still be the secondary prevention. Rapid HPV(DNA 
testing, 3 time per lifetime, would have excellent potential to be and effective and cost(effective 
strategy. Particularly, the strategy of vaccinating targeting young adolescent and screening 
and treat older women, could address social, economic and political organization to contribute 
in reducing cervical cancer incidence and mortality in developing countries (Tsu et al., 2008).  
		
The sensitivity of HPV(DNA assays for the detection of CIN2+ is high, although they cannot 
discriminate transient infections from persistent infections, thus lacking in specificity. 
Consequently, there is motivation to evaluate more disease(specific biomarkers, able to 
identify women susceptible to progression. Ideally the candidate marker, defining the 
different stages (clearance, persistence, progression) of cellular changes associated with 
HPV infection, should give a high positive predictive value in predicting progression to 
cervical cancer. Recently, guidelines have been proposed for the development of biomarker(
based screening toll for early detection of cancer, which can be categorized into five phases: 
1) preclinical exploratory studies for marker discovery; 2) clinical assay development and 
validation; 3) retrospective longitudinal repository studies; 4) prospective screening; 5) 
cancer control studies, including cost(benefit analysis. 
Potential markers of progression include HPV viral load, DNA methylation, HPV(DNA 
sequences integrated into the host genome, over(expression of cell(cycle regulator proteins 
or proliferation markers, telomerase and messenger RNA for E6 and E7 oncoproteins. Here, 
we will restrict the discussion to the markers which have been evaluated in large clinical 
trials and reached some level of clinical applicability. 
$%%	
HR(HPV viral load has been suggested to be a useful marker in distinguishing infection of 
clinical relevance (48, 49). Among women with HPV(DNA positivity, cytological abnormalities 
are more common in those having high viral load (Lilli et al., 2005; Xi et al., 2011).  
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However, it is now clear that the liaison between viral load and cervical disease is more 
complex that it was previously thought. (De Oer et al., 2007). Many cross(sectional studies 
reported an increased viral load with growing disease severity, but others found no 
association (50). There are some probable reasons for these contradictions: HPV integrated 
status increases with enhancing of disease severity; integration status is characterized by a 
declined viral replication. Thus paradoxically, the risk of disease progression is not 
associated to the rate of viral replication but is sometimes just the opposite! (Denis et al., 
2008). In our retrospective longitudinal analysis, we did not observe a significant association 
between semi(quantitative value of viral load and low(grade cervical lesions outcome 
(Zappacosta R et al, data not shown). In addition, the relationship between viral load and 
cervical disease varies among oncogenic HPV types. Studies using quantitative type(specific 
PCR for HR(HPV 16, 18, 31, 33 and 45 and LR(HPV 6 and 11 showed that HPV(16 can reach 
a much higher viral load than the other above listed types and that only HPV(16 viral load 
might correlate with increased severity of cervical disease (Saunier et al., 2008). Then, all 
oncogenic HPV types but 16 are able to provoke cervical cancer, even when they are present 
at low levels (Boulet et al., 2008).  
.1"	

More recently, epigenetic alteration of genome of HPV(infected cells have been considered 
as diagnostic marker for cervical cancer. Aberrant presence of CpG(rich DNA sequences (the 
so(called CpG islands) in the promoter region of tumor suppressor genes, represents one of 
the several epigenetic changes that contribute to carcinogenesis (Esteller et al., 2002). DNA 
methylation involves the covalent addition of a methyl ((CH3) group at the carbon(5 
position of a cytosine that precedes a guanosine. Usually, DNA methylation plays a role in 
maintaining genome stability and in regulating gene expression (Jung et al., 2011). However, 
global hypermethylation of CpG clusters located in the promoter region of multiples genes 
have been associated with malignancy (Ehrlich, 2002). Numerous clinical studies 
demonstrated that these epigenetic methylation changes are often present in a variety of 
cancer. In this framework, silencing of the Tumor Suppressor Lung Cancer 1 (TSLC1) gene 
by promoter hypermethylation may be a valuable biomarker to detect cervical lesions with 
high malignancy potential. TSLC1 was found to be silenced in 91% of cervical cancer cell 
lines, primarily resulting from promoter hypermethylation (Yang et al., 2006). Moreover, 
such hypermethylation was detected in 58% of cervical carcinomas and in 35% of CIN2+ 
lesions, but not in low(grade CIN or in normal cervix (Fenq et al., 2005). The high frequency 
of TSLC1 methylationin in cervical cancer was confirmed by studies of Li et al., (Li et al., 
2005) and Gustafson et al. (Gustafson et al., 2004). These data suggest that the analysis of 
methylation patterns of TSLC1 gene maight be a valuable tool in forthcoming screening 
programs; however, they appear more likely to play a role in detecting cervical cancer cell 




Viral integration often occurs at the E2 gene of the HPV genome. Disruption of the E2 gene 
is believed to result in more intensive transcription of the oncogenes E6 and E7. In the 
episomal state, E2 and E6 DNA are present in equal amounts, while in the integrated form, 
less intact E2 is present (zur Hausen, 2002). Then, a decrease in E2/E6 DNA ratio assessed 
with real(time PCR would be a valuable potential progression marker.  
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Expression of  Ki(67 protein occurs in proliferating cells and its presence is normally 
confined to the basal or suprabasal epithelial cells layers. Expression of Ki(67 allows 
distinction of negative atrophic cells and positive neoplastic cells in menopausal women. 
Expression beyond the inner third of the cervical epithelium  is observed in case of CIN and 
cancer. Several authors have found a significant correlation between the presence/intensity 
of Ki(67 and the severity of cytological abnormality in cytological preparation (Luzzatto et 
al., 2004; Sahebali et al., 2003). However, deeper analysis did not confirm the initially 
hopeful results and showed that these markers did not have adequate sensitivity and 
specificity to supply the request of additive prognostic markers, in cytological screening 
(Wentzensen & von Knebel Doeberitz, 2007). 
Several other proteins are overexpressed in proliferating cells. So, certain cell progression 
regulators have been proposed as potential markers for cervical neoplasia: Proliferating Cell 
Nuclear Antigen (PCNA), Mcm5, Cdc6 and Cyclin E. Proliferation markers are 
physiologically present in basal and parabasal cells, and are an objective indicator of 
neoplasia when observed beyond the lower cell layers. In cervical smears, lacking 
architectural information, the presence of proliferation markers is less informative and can 
easily yield false(positive results.  
'*	
Telomerase are repeated arrays of six nucleotides (TTAGGG) at the chromosome ends that 
protects chromosomes against degradation, aberrant fusion or recombination. They become 
progressively shorter as cells multiply, resulting in chromosomal instability and senescence 
when a critical short length is reached. The enzyme telomerase is a ribo(nucleoprotein 
composed of two parts: an RNA part (hRT) and a catalytic part (hTERT), which controls 
telomere length. hTERT is believed to play a role in cells immortalization. Its activity in 
increased in CIN and cancer (Barbosa et al., 2011).  The intensity of telomerase activity is 
reported to be correlated with the severity of the abnormality, both in cervical biopsies and 
cytology. However, reliable detection of hTR, hTERT and telomerase activity is still limited 




Cyclin(dependent kinases (CDKs), cyclins and CDK inhibitors are key molecules that control 
the cell cycle and coordinate DNA synthesis, chromosome separation and cell division. The 
cyclin(dependent kinase inhibitor p16 INK4a prevent the CDK4/6 interaction with cyclin D1, 
thus stopping progression of cell cycle through the G1/S checkpoint. Usually, HPV(E7 
oncoprotein is expressed only in terminally differentiated superficial cell layers of the cervical 
epithelium, Several factors, such as loss of cellular inhibiting factors and integration of HPV 
genome into the host genome, can lead to the expression of E7 in basal cell layers. The result is 
the cellular transformation and the massive accumulation of p16 ink4A into cells. Accumulation 
of p16 mRNA and related protein has been reported in response to inactivation of the 
retinoblastoma gene product (pRb), through binding with viral E7 oncoprotein. p16 is then 
overexpressed at very low levels in normal cells, while it is strongly over(expressed in cervical 
cancer cell lines, in which pRB has been inactivated by E7  (Lambert et al., 2006). 
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The usefulness of immunocytochemical detection of p16 overexpression in cervical samples 
has been shown in many trials and has been widely accepted, especially as reflex test for the 
triage of equivocal or mildly abnormal Pap cytologic results. In triaging ASC(US and LSIL 
cases, it has been shown that p16 immunocytochemical analyses might provide similar 
sensitivity for the detection of underlying CIN2+ lesions as HPV testing, but at significantly 
higher specificity level (Denton et al., 2010). A recent meta(analysis (Tsoumpou et al., 2009), 
showed a substantial variability in the literature regarding the cut(off for positive p16 
results; this variability was  probably due to the wide range of colorbased qualitative 
(nuclear or cytoplamatic positivity, staining intensity, etc.) and quantitative parameters (ie, 
number of immunoreactive cells), which singly or in combinations could be use for the 
evaluation of results. The purely colour(based approaches to identify abnormal cells in 
cervical smears using p16INK4a, is hampered by the fact that some normal endocervical, 
endometrial, intercalated, squamous metaplastic or atrophic cells may also display p16(
immunoreactivity. For this reason, it was proposed the evaluation of a score based on a 
four(tiered classification of nuclear abnormalities of p16(positive cells, to discriminate 
between no abnormal nuclei (score 1), slightly abnormal nuclei (score 2), clearly abnormal 
nuclei (score 3), and severely abnormal nuclei (score 4).  Nuclei from normal(intermediate 
cells or polymorphonuclear granulocytes were used as an internal size, shape, staining, and 
texture standard (Wentzenses et al., 2005). Despite NS classification, there are still 
disagreement in literature regarding the utility of p16 INK4a tool, both as locator of high(grade 
cervical cells(positive cell as well as interpreter, for the predictive assessment of potential 
abnormal cells. Disagreements are based on the common conviction about the poor 












Under physiological conditions, the simultaneous expression of a protein with a tumor(
suppressive function (p16) and a proliferation marker (Ki(67) mutually excludes each other. 
Vice versa, simultaneous detection of p16 overexpression and expression of proliferation 
marker K1(67 within the same cervical epithelial cell indicates deregulation of the cell cycle. 
In this context, it has been proposed the use of the immunocytochemical evaluation of p16(
Ki(67 coexpression to identify esocervical cells with deregulated cell cycle, independently 
from morphology(based interpretation parameters (Galgano et al., 2010). The presence of 
one or more double(immunoreactive cell may be considered positive and indicative of 
underlying CIN2+ lesion (Schmidt D et al., 2011). The European Equivocal or Mildly 
Abnormal Papanicolaou Cytology Study (EEMAPS) evaluated the performance of the new 
immunocytochemical p16/Ki(67 dual(stain protocol (CINtec+ assay, mtm laboratories AG, 
Heidelberg, Germany) in the triage of ASC(US and LSIL lesions. Results from this study 
showed a high sensitivity of CINtec+ test for the detection of underlying CIN2+ lesions in 
women with ASC(US and LSIL cytology, comparable to sensitivity showed by HPV testing 
and p16 single(stain cytology. Particularly, Schmidt et al., showed that, in ASC(US triage, 
p16/Ki(67 dual(stain identified the same proportion of underlying CIN2+ lesions as HPV 
testing, but significantly reducing the number of women which would need referral to 
colposcopy, especially in younger population. Regarding  CINtec+ dual(stain specificity, 
this was significantly improved in comparison with that of p16 single(stain approach. 
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In a recent retrospective analysis, conducted within the regional organized screening 
program of Abruzzo region (Italy), in which Hybrid Capture 2 test is used in primary 
screening, we analyzed the diagnostic performances of p16INK4a/Ki67 dual(stained cytology 
in identifying CIN2+ lesion in 372 HPV(DNA positive women triaged for LSIL(or(worse 
(LSIL+) Pap cytology (unpublished data). Preliminary results showed that reflex CINtec+ 
test improved significantly sensitivity and NPV of cytology alone in triaging LSIL+ lesions 
(90.8%   62% and 77.2%   88.3%, respectively), but reduced triage cytology specificity and 
PPV (42.6%   79.6% and 49.4%   65.2%, respectively). In this context we believe that 
p16/Ki67 cytology, as a reflex test, may efficiently complement HPV(based screening 
programs to prevent cervical cancer, but follow(up studies are needed to assess its effective 





As previously described, one of the key consequences of HPV(induced chromosomal 
instability is the integration of HPV genome into the host(cell genome together with the 
continuous and deregulated expression of E6/E7 viral oncogenes. Then persistent 
expression of E6/E7 is a necessary step for HPV(induced carcinogenesis. 
E6 expression is regulated at transcriptional or post(transcriptional level. HPV(16 E6 ORF 
encodes for three different variants of E6 protein, which may have dissimilar roles in the 
viral cell cycle. These transcripts are either unspliced (full length(FL( E6 transcripts) or 
spliced (Figure 4). Interestingly, only FL E6 protein has been found to be powerfully bound 
to p53, thus promoting its degradation. Moreover, only the unspliced E6 form was found to 
be more strongly associated with tumorigenicity. Studies carried out on cervical cancer 
samples show that FL transcripts are always present (Wise(Draper, & Wells, 2008). These 
studies indicate FL transcripts as being the most important biomarkers for the carcinogenic 
process (Asadurian et al., 2007).  Then, tests for the detection of E6/E7 mRNA seems to be 
promising in increasing HPV testing specificity. 
 
Fig. 4. Full length E7 transcripts in relation to HPV life cycle 
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Various in(house assays for E6/E7 mRNA detection have been described, most of which 
have employed a reverse transcription PCR approach, focusing on HPV(16 and (18. Now, 
two commercial RNA assays are available: the Nuclisens EasyQ HPV assay (biomérieux 
S.A., France), in certain countries distribuited as the PreTect HPV(Proofer® assay (Norchip 
AS, Klokkarstua, Noway), and the Aptima®  HPV Assay (Gen(Probe Incorporated, San 
Diego, CA) .  
Both assays are compatible with samples collected in cytology media. 
Nuclisens EasyQ HPV assay is a multiplex nucleic acid sequence amplification (NASBA) 
method, detecting FL transcripts of E6/E7 oncoproteins in a DNA background is 
commercially available from two companies; they are the and (Boulet et al., 2008). The test is 
based on the molecular beacon probe technology and on the real(time detection of five 
oncogenic HPV types (16, 18, 31, 33 and 45). Molecular beacons are oligonucleotide probes 
consisting of stem(loop structure and of two regions: loop region, is a single(stranded 18(30 
base pair sequence that is complementary to the target sequence; stem region, typically 
consists of 5(7 base pair long double(stranded sequences that lie on both arms of loop 
region; 5’ sequences are labeled with a fluorescent dye (fluorophore) while 3’ sequences are 
covalently labeled with a non(fluorescent quencher. In absence of a complementary target 
sequence, molecular beacon remains closed and in a nonhybridized state; in this situation, 
the quencher captures the fluorescent signal. When beacon unfolds the presence of the 
complementary target (E6/E7 mRNA), loop region hybridizes with this sequence, 
fluorophore separates itself from the quencher, and the fluorescent signal is transmitted 
(Figure 5). 
In Nuclisens procedure, two different labeled molecular beacon probes for each multiplex 
reaction are used. Fluorescein (FAM) is used as fluorophore for the detection of HPV(16, 31, 
and 33; Texas Red (TxR) as fluorophore for the detection of U1A gene, HPV(18, and HPV(45. 
U1A is a small nuclear specific ribonucleoprotein A included in HPV(Proofer kit to avoid 
false(negative results, and to monitor sample mRNA integrity. NASBA amplification is 
achieved through coordinated activities of three enzymes (Avian Myeloblastosis Virus 
Reverse Transcriptase,  Rnase H and T7 RNA polymerase) and two DNA 
oligonucleotide primers that are specific for the target sequence of interest. RNA 
amplification is performed for one hundred and fifty minutes at isothermal temperature of 
41 ºC. In presence of the target sequences, a fluorescent signal is observed. A fluorescent 
analyzer measures, in real(time, the emitted fluorescence from molecular beacon hybridized 
with amplified mRNA (Varnai et al., 2008). 
Cuschieri et al., carried out a follow(up study on 54 HPV(DNA positive samples obtained 
from 3,444 cytologically normal women. Samples which were PreTect HPV(Proofer(positive 
over 9 months (persistence), were proven to have CIN3 in most cases (Cuschieri et al., 2004). 
This study showed the strict correlation between E6/E7 mRNA expression and oncogenic 
HPV(DNA persistence, moreover detecting a mRNA test specificity higher (81%) than 
DNA(based methods (44%). Cuschieri concluded that mRNA test (PreTech or Nuclisens) 
would find persistent HPV infection and would reduce the need for follow(up or repeated 
test, that will be sometime necessary if DNA(based technology is used.  
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Fig. 5. NASBA technology. A – molecular beacon in absence of target sequence; B – 
molecular beacon unfolds the presence of the complementary target and transmits 
fluorescent  
The high clinical accuracy of E6/E7 mRNA test has been confirmed by a large cross(
sectional study, carried out on about 4,000 women older than 30 years assessed 
longitudinally for a minimum of 2 years, based on detection of HPV(DNA and E6/E7 
mRNA. Cytological and histological data related to follow(up were also included (Molden 
et al., 2005). DNA and RNA test showed identical sensitivity to detect CIN2+ lesion, but the 
specificity for RNA and DNA test was 85% and 50% respectively. Benevolo et al carried out  
a retrospective study to evaluate the performance of mRNA test as a triage test for cytology 
and HPV DNA testing. The study analyzed 1,201 women, 688 of whom had a colposcopy 
follow(up and 195 of whom had histology(confirmed CIN2+ lesion. Diagnostic accuracy for 
CIN2+ were determined for mRNA test in comparison to HPV(DNA test and cytology. 
Stratifying by cytological grades, mRNA test sensitivity ranged from 62% to 83%. The 
corresponding figures for DNA testing ranged from 91% to 96%. Specificity values  for 
mRNA test and DNA test ranged from 45% to 82% and from 4% to 29%, respectively. Used 
as a triage test for ASC(US and L(SIL, mRNA test reduced colposcopies by 69(79%, while 
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DNA testing reduced colposcopies by 15(38%. As a HPV(DNA positivity triage, mRNA test 
reduced colposcopies by 63%, whereas cytology at the ASC(US+ threshold reduced 
colposcopies by 23% (Benevolo et al., 2011). 
These data, combined with others 15 extensive studies carried out in many countries, show 
that mRNA test might reduce the number of ASCUS and LSIL cases to be followed by 
colposcopy(directed biopsies by more than 70% (Nakagawa et al., 2000). Then, 
overexpression of E6/E7 for carcinogenic HPV types might prove a specific and predictive 
marker of precancerous lesions that need clinical attention. At present, only the above listed 
five oncogenic HPV types are detectable by Nuclisens technology; at the first sight this may 
be considered a disadvantage in comparison with the available DNA genotyping strategies. 
However, studies carried out to find E6/E7 mRNA in cervical smears of women with 
cervical cancer, demonstrated a 100% coverage by these genotypes (Kraus et al., 2006; 




APTIMA®  HPV Assay (Gen(Probe Incorporated, San Diego, CA) is a target amplification 
nucleic acid probe test for the in vitro qualitative detection of E6/E7 mRNA from 14 
oncogenic HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), in LBC specimens. 
The assay provides a qualitative result (positive/negative) for the presence/absence of these 
oncogenic HPV types, but does not determine the specific HPV type present in the 
specimen.This technology amplifies target mRNAs using transcription(mediated 
amplification (TMA) and detects the amplification products using nucleic acid probes  
without specific distinction among the specific HPV types implicated. 
APTIMA HPV Assay involves three main steps, which take place in a single tube: capture, 
amplification and detection. To capture the target mRNA, HPV(specific capture oligomers 
and magnetic microparticles are used. Target mRNA is amplified by transcription(mediated 
amplifications (TMA) and using two enzymes: Moloney murine leukemia virus reverse 
transcriptase and T7 RNA polymerase. Targeted amplification is achieved using primers 
that hybridize to conserved regions of oncogenic E6/E7 mRNA.  The detection of the 
amplification products (amplicons) is carried out through dual kinetic assay . Specifically, 
analyte amplicons are detected using 2(methyl acridinium ester(labeled probes, which 
hybridized to conserved region of carcinogenic HPV types. An fluoro(acridium ester(labeled 
probe is used to detect internal control amplicon added to each reaction to verify the 
performance of each step of the assay.  
Positive and negative calibrators are used to determine the validity of the run and to 
establish the assay cut(off values for the internal control and analyte signals. 
Chemiluminescent signal observed for each reaction is measured using a luminometer, and 
compared to the cut(off values. Specimens with cut(off (S/CO) ratio ≥1.00 are considered 
positive. Samples with S/CO ratio %1.00 must have an internal control signal greater than or 
equal to the internal control cut(off value and may be considered a valid negative result. 
FASE (French APTIMA Screening Evaluation) study was the first trial comparing Aptima 
mRNA test with LBC and HC2 (Monsonego et al., 2011). Data from about 4,500 Parisian 
women have been analyzed. Results showed that the sensitivity of Aptima mRNA test for 
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detecting CIN2+ lesions was similar to that offered by HC2 test but is significantly higher 
than that of LBC. In addition, the specificity of Aptima was significantly higher than that of 
both HC2 and cytology.  
Actually, for its characteristics, Aptima test is considered to be the ideal assay for primary 
cervical cancer screening, offering good specificity without losing sensitivity. The use of 
APTIMA HPV Assay would reduce the number of false positive results compared to DNA 
assays, helping limit the number false positive results leading to inappropriate and costly 
diagnostic procedures, over(treatment and needless anxiety in women. 
On the other hand, PreTect HPV(Proofer/Nuclisens EasyQ HPV mRNA tests with their 
high specificity and PPV, is considered helpful in the clinical work(up of DNA(positive 
women, particularly of those with ASC(US/LSIL cervical abnormalities, also in 
consideration of its flexibility when used in LBC samples, stored at room temperature in 
cytological biobanks. 
Basing on these consideration, mRNA(based technology would certainly increase the 
diagnostic accuracy of cervical abnormalities, through a better identification of HPV 
infection which are more likely to persist and induce CIN2+ lesions in future, and by 




Persistent HPV infection has proven to be important in predicting cell abnormalities. Hence, 
a supplementary method should reveal HPV persistence and preferentially give additional 
information about the outcome of the disease. The ideal test should then reveal optimal 
analytical and clinical accuracies. Analytical accuracy of a test merely refers to the ability of 
detection of an endpoint. Clinical accuracy is a parameter which is more related to medical 
practice: it expresses the ability of the test to detect a relevant phase of disease. 
Studies summarized above resulted in a long list of candidate tools which may improve Pap 
test in the early detection of cervical cancer. Most of these markers have not yet passed the 
first phases of validation but surely, their number is expected to expand, as more genomic 
and proteomic studies will appear in the near future. 
Before integrating the ideal marker into clinical practice, deeper clinical validation studies 
are needed, particularly longitudinal assessment to prospectively evaluate its clinical 
performances. At the moment, it is difficult to predict which of those markers or marker 
panels are ultimately the most promising candidates, also considering the shift to primary 
HPV screening. 
Currently, most national vaccination program are primarily aimed to preadolescents and 
adolescents. It is an extremely positive fact to hope in use of a vaccine capable to prevent a 
neoplasia with so strong social impact such as cervicocarcinoma. However, there are several 
issues that still need to be addressed before the fully appreciation of HPV vaccination in 
matter of overall potential and impact for public health (Psirry & Di Maio, 2008; Stanley et 
al., 2006). First, the duration of protection is unknown. Second, bivalent vaccination will 
only protect against HPV(16 and 18. Third, prophylactic vaccines are likely to provide 
limited benefits to women previously infected with oncogenic HPVs. Fourth, vaccines are 
relatively expensive and vaccine delivery in developing world is more difficult. Fifth, the 
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effects of vaccination on the female psychology could be dangerous: if vaccinated women 
will believe to be at no further risk of developing HPV(induced cancer and will leave 
screening programs, the last impact of vaccination on the incidence of cervicocarcinoma will 
be invalided (Welters et al., 2008). 
It is therefore important that both, women and healthcare professionals, do not perceive 
HPV vaccination as an immediate alternative to cervical cancer screening, because only 
integrating HPV vaccination into screening programs will maximize the benefits offered by 
vaccine and will lead to a greater reduction of cervical cancer prevalence, incidence, and 
mortality. It was recently reported that , if both HPV testing and vaccination are performed, 
the total number of annual number of Pap tests is predicted to be reduced by 43% (Logatto(
Filho & Schmitt, 2007). In this context, the nature of the screening and the management of 
women must to be adapted to the new technologies. 
In conclusion, moving the diagnostics from the cellular level into the molecular level allows 
not only to better identify cervical precancerous states, but also to prevent cervical 
pathology in the stage of molecular changes. In this context, the management of women 
with HPV infection would be based on risk categories rather than on specific assay results. 
This tailored cervical cancer risk assessment give hope for the improvement of effectiveness 
of cervical cancer prevention and for a significant reduction of screening costs.  
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